Is aggressive adjuvant chemotherapy the Halsted radical of the '80s?

Abstract

CA: A Cancer Journal for CliniciansVolume 34, Issue 6 p. 345-351 OpinionFree Access Is aggressive adjuvant chemotherapy the halsted radical of the ‚80s? Rose Kushner, Rose Kushner The founder and Executive Director of the Breast Cancer Advisory Center in Kensington, MarylandSearch for more papers by this author Rose Kushner, Rose Kushner The founder and Executive Director of the Breast Cancer Advisory Center in Kensington, MarylandSearch for more papers by this author First published: November/December 1984 https://doi.org/10.3322/canjclin.34.6.345Citations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Maguire P, Van Dam F: Psychological aspects of breast cancer: Workshop report. Eur J Cancer Clin Oncol 19: 1735– 1740, 1983. 2 Palmer BV, Walsh GA, McKinna JA, et al: Adjuvant chemotherapy for breast cancer: Side effects and quality of life. Br Med J 281: 1594– 1597, 1980. 3 Van Dam F, Linsen ACG, Conzijn MA: Evaluating quality of life: Behavioural measures in cancer clinical trials, in M Staquet, R Sylvester, M Bayste (eds): The Practice of Clinical Trials in Cancer. Oxford, England, Oxford University Press, 1983. 4 Morris T: The impact of the organization of treatment for breast cancer on quality of life. Experientia 41 (suppl): 381– 387, 1982. 5 XII International Cancer Congress (UICC), Buenos Aires, Argentina, September 1978. 6 XIII International Cancer Congress (UICC), Seattle, Washington, United States, September 1982. 7 Reviews in Endocrine-Related Cancers: Fundamental Problems in Breast Cancer, Jasper, Canada, September 17--18, 1982, symposium sponsored by the Cross Cancer Institute, Edmonton, Canada. 8 Meakin JW: Is there a place for adjuvant endocrine therapy of breast cancer in endocrine treatment of breast cancer? Recent Results Cancer Res 71: 178– 184, 1980. 9 Henderson IC, Canellos GP: Cancer of the breast: The past decade. N Engl J Med 302: 17– 30, 1980. 10 Stoll BA: Breast cancer: Rationale for endocrine therapy, in BA Stoll (ed): Hormonal Management of Endocrine-Related Cancer. London, Lloyd-Luke Ltd, 1981, pp 77– 91. 11 Fisher B, Wolmark N: The current status of systemic adjuvant treatment in the management of primary breast cancer. Surg Clin North Am 61: 1347– 1360, 1981. 12 Asire A, SEER program. National Cancer Institute, Bethesda, Md, personal communication, 1984. 13 Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405– 410, 1976. 14 Levitt SH, Potish RA: The case for adjuvant CMF chemotherapy in breast cancer. Has it been made? Cancer Clin Trials 4: 363– 369, 1981. 15 Consensus Development Conference on Adjuvant Chemotherapy and Breast Cancer, sponsored by the Office for Medical Applications of Research, National Institutes of Health, Bethesda, Md, July 14--16, 1980. 16 Hubay CA: Statement made at meeting on Adjuvant Therapy of Breast Cancer, September 1982, sponsored by Breast Cancer Task Force, National Cancer Institute, Bethesda, Md. 17 Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10– 15, 1981. 18 Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1– 6, 1981. 19 Hubay CA, Pearson OH, Marshall JS, et al: Adjuvant therapy of stage II breast cancer. Breast Cancer Res Treat 1: 77– 82, 1981. 20 Community Clinical Oncology Program, NIH Guide Supplement for Grants and Contracts, US Department of Health, Education, and Welfare, RFA No. 10-NIH-NCI-DRCCA, July 1982. 21 Fraumeni JF Jr, Miller RW: Drug-induced cancer. J Natl Cancer Inst 48: 1267– 1270, 1972. 22 International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Some Aziridines, N-, S- & O-Mustards and Selenium, vol 9. Lyon, France, World Health Organization, 1975. 23 Curtis RE, Hankey BF, Myers MH, et al: Risk of leukemia associated with the first course of cancer treatment: An analysis of the Surveillance, Epidemiology and End Results program experience. J Natl Cancer Inst 72: 531– 544, 1984. 24 Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727– 1733, 1979. 25 Ling V: Genetics of drug resistance in mammalian cells, in N Bruchovsky, JH Goldie (eds): Drug and Hormone Resistance in Neoplasia: Basic Concepts, vol 1. Boca Raton, Fla, CRC Press Inc, 1983, pp 1– 19. 26 Yunis JJ: The chromosomal basis of human neoplasia. Science 221: 227– 236, 1983. 27 Fidler IJ: Recent concepts of cancer metastasis and their implications for therapy. Cancer Treat Rep 68: 193– 198, 1984. 28 Culliton BJ: Breast cancer: Reports of new therapy are greatly exaggerated. Science 191: 1029– 1031, 1976. 29 Feinstein AR, Horwitz RI: Double standards, scientific methods, and epidemiologic research. N Engl J Med 307: 1611– 1617, 1982. 30 Sackett DL: The competing objectives of randomized trials (editorial). N Engl J Med 303: 1059– 1067, 1980. 31 Byar DP, Head, Clinical and Diagnostic Trials Section, Biometry Branch, National Cancer Institute, Bethesda, Md, personal communication, 1982. 32 Dao TL, Nemoto T: Clinical significance of skin recurrence after radical mastectomy in women with cancer of the breast. Surg Gynecol Obstet 117: 447, 1963. 33 Lippman ME, Chief, Breast Clinic, National Cancer Institute, Bethesda, Md, personal communication, 1982. 34 Protocol Data Query (PDQ), Phase III chemohormonal therapy with CTX/MTX/5-FU/ TMX for patients with no evidence of disease following resection or radiotherapy for stage III/ IV or recurrent breast cancer, National Cancer Institute, Bethesda, Md, NCI-MB-164, NCI-82-C-129, NCI-T83-1159N, 1982. 35 McGuire WL, Horwitz KB, Zava DT, et al: Estrogen and progesterone receptors in human breast cancer, in EB Thompson, ME Lippman (eds): Steroid Receptors and the Management of Cancer, vol 1. Boca Raton, Fla, CRC Press Inc, 1979, p 31. 36 Blumenschein GR: Presented at Reviews in Endocrine-Related Cancers: Fundamental Problems in Breast Cancer, Jasper, Canada, September 17--18, 1982, symposium sponsored by the Cross Cancer Institute, Edmonton, Canada. Proceedings, to be published. 37 Hortobagyi GN: Presented at Reviews in Endocrine-Related Cancer: Fundamental Problems in Breast Cancer, Jasper, Canada, September 17--18, 1982, symposium sponsored by the Cross Cancer Institute, Edmonton, Canada. Proceedings, to be published. 38 Shimkin M, Professor Emeritus, Division of Epidemiology, Department of Community and Family Medicine, School of Medicine of the University of California, San Diego, La Jolla, Calif, personal communication, 1982. 39 Fisher B, Redmond C, Brown A, et al: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1: 227– 241, 1983. 40 Clark GM, McGuire WL, Hubay CA, et al: Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 309: 1343– 1347, 1983. 41 Baum M, Brinkley DM, Dossett JA, et al: Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: Interim analysis at four years by Nolvadex Adjuvant Trial Organization. Lancet 1: 257– 261, 1983. 42 Bonadonna G, Rossi A, Tancini G, et al: Adjuvant chemotherapy in breast cancer (letter). Lancet 1: 1157, 1983. 43 Lippman ME: Presented to the Sixth Annual San Antonio Breast Symposium, San Antonio, Texas, November 5, 1983. 44 Zubrod CG: ORIGINs and development of chemotherapy research at the National Cancer Institute. Cancer Treat Rep 68: 9– 30, 1984. 45 Controversies in Surgery: Breast Disease, symposium sponsored by the Cleveland Clinic, Cleveland, Ohio, February 9--10, 1984. 46 Fourth International Conference on the Adjuvant Therapy of Cancer, Tucson, Arizona, 1984, sponsored by the University of Arizona Cancer Center. Proceedings, New York, Grune & Stratton Inc, to be published. 47 Carter SK: Presentation to the Sixteenth Annual Southeastern Wisconsin Cancer Conference, Madison, Wis, May 12, 1984. 48 Salmon SE: Presentation to the National Cancer Advisory Board, Bethesda, Md, May 14, 1984. 49 Jacobi Y, Acting Director, Office for Medical Applications of Research, National Institutes of Health, Bethesda, Md, personal communication, 1984. Citing Literature Volume34, Issue6November/December 1984Pages 345-351 ReferencesRelatedInformation